​

Anavex Life Sciences (AVXL) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

AVXL Stock Forecast

Anavex Life Sciences (AVXL) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $11.00, with a high of $11.00 and a low of $11.00. This represents a 22.91% increase from the last price of $8.95.

$3 $4 $5 $6 $7 $8 $9 $10 $11 High: $11 Avg: $11 Low: $11 Last Closed Price: $8.95

AVXL Stock Rating

Anavex Life Sciences stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (91.67%), 1 Hold (8.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 1 11 Strong Sell Sell Hold Buy Strong Buy

AVXL Price Target Upside V Benchmarks

TypeNameUpside
StockAnavex Life Sciences22.91%
SectorHealthcare Stocks 35.94%
IndustryBiotech Stocks 83.61%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$8.95$8.95$8.95
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2512---3
Mar, 2512---3
Feb, 2512---3
Jan, 2512---3
Dec, 2412---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 06, 2022Cantor Fitzgerald$11.00$8.5428.81%22.91%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 18, 2024H.C. WainwrightBuyBuyhold
Jul 22, 2024EF HuttonBuyinitialise
Jan 03, 2023BarclaysEqual-WeightEqual-Weighthold
Dec 06, 2022Cantor FitzgeraldNeutraldowngrade

Financial Forecast

EPS Forecast

$-5 $2 $9 $16 $23 $30 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-0.60$-0.52-----
Avg Forecast$-0.63$-0.54$-0.60$2.35$3.68$10.73$13.07
High Forecast$-0.61$0.08$0.08$5.03$7.46$22.96$27.97
Low Forecast$-0.65$-1.16$-1.29$-0.33$-0.11$-1.50$-1.83
Surprise %-4.76%-3.70%-----

Revenue Forecast

$0 $800M $2B $2B $3B $4B Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported-------
Avg Forecast-$9.40M$14.38M$334.26M$543.30M$1.51B$1.98B
High Forecast-$14.92M$26.98M$665.12M$1.02B$2.84B$3.72B
Low Forecast-$3.86M$1.77M$3.40M$66.99M$186.46M$244.28M
Surprise %-------

Net Income Forecast

$-500M $100M $700M $1B $2B $3B Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-47.51M$-43.00M-----
Avg Forecast$-50.27M$-43.00M$-53.39M$196.15M$360.29M$895.61M$1.09B
High Forecast$-48.70M$6.34M$7.04M$419.71M$622.67M$1.92B$2.33B
Low Forecast$-51.84M$-97.04M$-107.75M$-27.41M$-9.18M$-125.13M$-152.42M
Surprise %-5.49%------

AVXL Forecast FAQ

Is Anavex Life Sciences stock a buy?

Anavex Life Sciences stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Anavex Life Sciences is a favorable investment for most analysts.

What is Anavex Life Sciences's price target?

Anavex Life Sciences's price target, set by 12 Wall Street analysts, averages $11 over the next 12 months. The price target range spans from $11 at the low end to $11 at the high end, suggesting a potential 22.91% change from the previous closing price of $8.95.

How does Anavex Life Sciences stock forecast compare to its benchmarks?

Anavex Life Sciences's stock forecast shows a 22.91% upside, underperforming the average forecast for the healthcare stocks sector (35.94%) and underperforming the biotech stocks industry (83.61%).

What is the breakdown of analyst ratings for Anavex Life Sciences over the past three months?

  • April 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Anavex Life Sciences’s EPS forecast?

Anavex Life Sciences's average annual EPS forecast for its fiscal year ending in September 2025 is $-0.6, marking a 15.38% increase from the reported $-0.52 in 2024. Estimates for the following years are $2.35 in 2026, $3.68 in 2027, $10.73 in 2028, and $13.07 in 2029.

What is Anavex Life Sciences’s revenue forecast?

Anavex Life Sciences's average annual revenue forecast for its fiscal year ending in September 2025 is $14.38M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $334.26M, followed by $543.3M for 2027, $1.51B for 2028, and $1.98B for 2029.

What is Anavex Life Sciences’s net income forecast?

Anavex Life Sciences's net income forecast for the fiscal year ending in September 2025 stands at $-53.388M, representing an 24.15% increase from the reported $-43.002M in 2024. Projections indicate $196.15M in 2026, $360.29M in 2027, $895.61M in 2028, and $1.09B in 2029.